The endocannabinoid system and its therapeutic exploitation in multiple sclerosis: Clues for other neuroinflammatory diseases

Progress in Neurobiology

Volumn 160, Issue , 2018, Pages 82-100

  Chiurchiù, Valerio ^a,b   van der Stelt, Mario ^c   Centonze, Diego ^d,e   Maccarrone, Mauro ^a,b  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^c LEIDEN UNIVERSITY   (Netherlands)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

^e IRCCS NEUROMED   (Italy)

Author keywords

Cannabinoid; Clinical trials; Endogenous lipids; Inflammation; Neurodegeneration; Neurotransmission

Indexed keywords

ANANDAMIDE; CANNABIDIOL; CANNABINOID RECEPTOR; CHEMOKINE; CYTOKINE; DRONABINOL; ENDOCANNABINOID; LIGAND;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; CANNABIS SATIVA; CHRONIC PAIN; EX VIVO STUDY; HUMAN; HUNTINGTON CHOREA; IMMUNOPATHOGENESIS; IN VIVO STUDY; METABOLISM; MULTIPLE SCLEROSIS; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SPASTICITY; ANIMAL; INFLAMMATION;

ANIMALS; ENDOCANNABINOIDS; HUMANS; INFLAMMATION; MULTIPLE SCLEROSIS;

EID: 85032914856     PISSN: 03010082     EISSN: 18735118     Source Type: Journal    
DOI: 10.1016/j.pneurobio.2017.10.007     Document Type: Review

References (231)

1. Adams, R., Marihuana: harvey lecture, February 19, 1942. Bull. New York Acad. Med. 18 (1942), 705–730.
2. Ahn, K., Smith, S.E., Liimatta, M.B., Beidler, D., Sadagopan, N., Dudley, D.T., Young, T., Wren, P., Zhang, Y., Swaney, S., Van Becelaere, K., Blankman, J.L., Nomura, D.K., Bhattachar, S.N., Stiff, C., Nomanbhoy, T.K., Weerapana, E., Johnson, D.S., Cravatt, B.F., Mechanistic and pharmacological characterization of PF-04457845: a highly potent and selective fatty acid amide hydrolase inhibitor that reduces inflammatory and noninflammatory pain. J. Pharmacol. Exp. Ther. 338 (2011), 114–124.
3. Altamura, C., Ventriglia, M., Martini, M.G., Montesano, D., Errante, Y., Piscitelli, F., Scrascia, F., Quattrocchi, C., Palazzo, P., Seccia, S., Vernieri, F., Di Marzo, V., Elevation of plasma 2-arachidonoylglycerol levels in Alzheimer's disease patients as a potential protective mechanism against neurodegenerative decline. J. Alzheimers Dis. 46 (2015), 497–506.
4. Amor, S., Smith, P.A., Hart, B., Baker, D., Biozzi mice: of mice and human neurological diseases. J. Neuroimmunol. 165 (2005), 1–10.
5. Arévalo-Martín, A., Vela, J.M., Molina-Holgado, E., Borrell, J., Guaza, C., Therapeutic action of cannabinoids in a murine model of multiple sclerosis. J. Neurosci. 2003:1 (2003), 2511–2516.
6. Arévalo-Martín, A., Molina-Holgado, E., Guaza, C., A CB1/CB2 receptor agonist, WIN 55,212-2, exerts its therapeutic effect in a viral autoimmune model of multiple sclerosis by restoring self-tolerance to myelin. Neuropharmacology 63 (2012), 385–393.
7. Artmann, A., Petersen, G., Hellgren, L.I., Boberg, J., Skonberg, C., Nellemann, C., Hansen, S.H., Hansen, H.S., Influence of dietary fatty acids on endocannabinoid and N-acylethanolamine levels in rat brain, liver and small intestine. Biochim. Biophys. Acta 1781 (2008), 200–212.
8. Atwood, B.K., Mackie, K., CB2: a cannabinoid receptor with an identity crisis. Br. J. Pharmacol. 160 (2010), 467–479.
9. Bénard, G., Massa, F., Puente, N., Lourenço, J., Bellocchio, L., Soria-Gómez, E., Matias, I., Delamarre, A., Metna-Laurent, M., Cannich, A., Hebert-Chatelain, E., Mulle, C., Ortega-Gutiérrez, S., Martín-Fontecha, M., Klugmann, M., Guggenhuber, S., Lutz, B., Gertsch, J., Chaouloff, F., López-Rodríguez, M.L., Grandes, P., Rossignol, R., Marsicano, G., Mitochondrial CB1 receptors regulate neuronal energy metabolism. Nat. Neurosci. 15 (2012), 558–564.
10. Baker, D., Pryce, G., Croxford, J.L., Brown, P., Pertwee, R.G., Huffman, J.W., Layward, L., Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 404 (2000), 84–87.
11. Baker, D., Pryce, G., Croxford, J.L., Brown, P., Pertwee, R.G., Makriyannis, A., Khanolkar, A., Layward, L., Fezza, F., Bisogno, T., Di Marzo, V., Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J. 15 (2001), 300–302.
12. Ball, S., Vickery, J., Hobart, J., Wright, D., Green, C., Shearer, J., Nunn, A., Cano, M.G., MacManus, D., Miller, D., Mallik, S., Zajicek, J., The Cannabinoid Use in Progressive Inflammatory brain Disease CUPID trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis. Health Technol. Assess. 19 (2015), 1–198 (vii-viii, xxv-xxxi).
13. Banks, W.A., The blood-brain barrier in neuroimmunology: tales of separation and assimilation. Brain Behav. Immun. 44 (2015), 1–8.
14. Bari, M., Battista, N., Valenza, M., Mastrangelo, N., Malaponti, M., Catanzaro, G., Centonze, D., Finazzi-Agrò A., Cattaneo, E., Maccarrone, M., In vitro and in vivo models of Huntington's disease show alterations in the endocannabinoid system. FEBS J. 280 (2013), 3376–3388.
15. Battista, N., Bari, M., Tarditi, A., Mariotti, C., Bachoud-Lévi, A.C., Zuccato, C., Finazzi-Agrò A., Genitrini, S., Peschanski, M., Di Donato, S., Cattaneo, E., Maccarrone, M., Severe deficiency of the fatty acid amide hydrolase FAAH activity segregates with the Huntington's disease mutation in peripheral lymphocytes. Neurobiol. Dis. 27 (2007), 108–116.
16. Bauer, M., Chicca, A., Tamborrini, M., Eisen, D., Lerner, R., Lutz, B., Poetz, O., Pluschke, G., Gertsch, J., Identification and quantification of a new family of peptide endocannabinoids Pepcans showing negative allosteric modulation at CB1 receptors. J. Biol. Chem. 287 (2012), 36944–36967.
17. Benito, C., Núñez, E., Tolón, R.M., Carrier, E.J., Rábano, A., Hillard, C.J., Romero, J., Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively over expressed in neuritic plaque-associated glia in Alzheimer's disease brains. J. Neurosci. 23 (2003), 11136–11141.
18. Benito, C., Romero, J.P., Tolón, R.M., Clemente, D., Docagne, F., Hillard, C.J., Guaza, C., Romero, J., Cannabinoid CB1 and CB2 receptors and fatty acid amide hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis. J. Neurosci. 27 (2007), 2396–2402.
19. Bernal-Chico, A., Canedo, M., Manterola, A., Victoria Sánchez-Gómez, M., Pérez-Samartín, A., Rodríguez-Puertas, R., Matute, C., Mato, S., Blockade of monoacylglycerol lipase inhibits oligodendrocyte excitotoxicity and prevents demyelination in vivo. Glia 63 (2015), 163–176.
20. Bilsland, L.G., Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 mice. FASEB J. 20 (2006), 1003–1005.
21. Bisogno, T., Howell, F., Williams, G., Minassi, A., Cascio, M.G., Ligresti, A., Matias, I., Schiano-Moriello, A., Paul, P., Williams, E.J., Gangadharan, U., Hobbs, C., Di Marzo, V., Doherty, P., Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J. Cell Biol. 163 (2003), 463–468.
22. Blázquez, C., Chiarlone, A., Sagredo, O., Aguado, T., Pazos, M.R., Resel, E., Palazuelos, J., Julien, B., Salazar, M., Börner, C., Benito, C., Carrasco, C., Diez-Zaera, M., Paoletti, P., Díaz-Hernández, M., Ruiz, C., Sendtner, M., Lucas, J.J., de Yébenes, J.G., Marsicano, G., Monory, K., Lutz, B., Romero, J., Alberch, J., Ginés, S., Kraus, J., Fernández-Ruiz, J., Galve-Roperh, I., Guzmán, M., Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease. Brain 134 (2011), 119–136.
23. Blankman, J.L., Simon, G.M., Cravatt, B.F., A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem. Biol. 14 (2007), 1347–1356.
24. Brindisi, M., Maramai, S., Gemma, S., Brogi, S., Grillo, A., Di Cesare Mannelli, L., Gabellieri, E., Lamponi, S., Saponara, S., Gorelli, B., Tedesco, D., Bonfiglio, T., Landry, C., Jung, K.M., Armirotti, A., Luongo, L., Ligresti, A., Piscitelli, F., Bertucci, C., Dehouck, M.P., Campiani, G., Maione, S., Ghelardini, C., Pittaluga, A., Piomelli, D., Di Marzo, V., Butini, S., Development and pharmacological characterization of selective blockers of 2-Arachidonoyl glycerol degradation with efficacy in rodent models of multiple sclerosis and pain. J. Med. Chem. 59 (2016), 2612–2632.
25. Brown, I., Cascio, M.G., Wahle, K.W., Smoum, R., Mechoulam, R., Ross, R.A., Pertwee, R.G., Heys, S.D., Cannabinoid receptor-dependent and −independent anti-proliferative effects of omega-3 ethanolamides in androgen receptor-positive and −negative prostate cancer cell lines. Carcinogenesis 31 (2010), 1584–1591.
26. Browne, P., Chandraratna, D., Angood, C., Tremlett, H., Baker, C., Taylor, B.V., Thompson, A.J., Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequity. Neurology 83 (2014), 1022–1024.
27. Butti, E., Bacigaluppi, M., Rossi, S., Cambiaghi, M., Bari, M., Cebrian Silla, A., Brambilla, E., Musella, A., De Ceglia, R., Teneud, L., De Chiara, V., D'Adamo, P., Garcia-Verdugo, J.M., Comi, G., Muzio, L., Quattrini, A., Leocani, L., Maccarrone, M., Centonze, D., Martino, G., Subventricular zone neural progenitors protect striatal neurons from glutamatergic excitotoxicity. Brain 135 (2012), 3320–3335.
28. Cabranes, A., Venderova, K., de Lago, E., Fezza, F., Sánchez, A., Mestre, L., Valenti, M., García-Merino, A., Ramos, J.A., Di Marzo, V., Fernández-Ruiz, J., Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis. Neurobiol. Dis. 20 (2005), 207–217.
29. Calabrese, M., Magliozzi, R., Ciccarelli, O., Geurts, J.J., Reynolds, R., Martin, R., Exploring the origins of grey matter damage in multiple sclerosis. Nat. Rev. Neurosci. 16 (2015), 147–158.
30. Cambron, M., D'Haeseleer, M., Laureys, G., Clinckers, R., Debruyne, J., De Keyser, J., White-matter astrocytes, axonal energy metabolism, and axonal degeneration in multiple sclerosis. J. Cereb. Blood Flow Metab. 323 (2012), 413–424.
31. Carroll, C.B., Bain, P.G., Teare, L., Liu, X., Joint, C., Wroath, C., Parkin, S.G., Fox, P., Wright, D., Hobart, J., Zajicek, J.P., Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study. Neurology 63 (2004), 1245–1250.
32. Carter, G.T., Abood, M.E., Aggarwal, S.K., Weiss, M.D., Cannabis and amyotrophic lateral sclerosis: hypothetical and practical applications, and a call for clinical trials. Am. J. Hosp. Palliat. Care 27 (2010), 347–356.
33. Cassano, T., Calcagnini, S., Pace, L., De Marco, F., Romano, A., Gaetani, S., Cannabinoid receptor 2 signaling in neurodegenerative disorders: from pathogenesis to a promising therapeutic target. Front. Neurosci., 11, 2017, 30.
34. Celorrio, M., Fernández-Suárez, D., Rojo-Bustamante, E., Echeverry-Alzate, V., Ramírez, M.J., Hillard, C.J., López-Moreno, J.A., Maldonado, R., Oyarzábal, J., Franco, R., Aymerich, M.S., Fatty acid amide hydrolase inhibition for the symptomatic relief of Parkinson's disease. Brain Behav. Immun. 57 (2016), 94–105.
35. Centonze, D., Rossi, S., Prosperetti, C., Tscherter, A., Bernardi, G., Maccarrone, M., Calabresi, P., Abnormal sensitivity to cannabinoid receptor stimulation might contribute to altered gamma-aminobutyric acid transmission in the striatum of R6/2 Huntington's disease mice. Biol. Psychiatry 57 (2005), 1583–1589.
36. Centonze, D., Bari, M., Rossi, S., Prosperetti, C., Furlan, R., Fezza, F., De Chiara, V., Battistini, L., Bernardi, G., Bernardini, S., Martino, G., Maccarrone, M., The endocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis. Brain 130 (2007), 2543–2553.
37. Centonze, D., Bari, M., Rossi, S., Prosperetti, C., Furlan, R., Fezza, F., De Chiara, V., Battistini, L., Bernardi, G., Bernardini, S., Martino, G., Maccarrone, M., The endocannabinoid system in targeting inflammatory neurodegenerative diseases. Trends Pharmacol. Sci. 28 (2007), 180–187.
38. Chagas, M.H., Zuardi, A.W., Tumas, V., Pena-Pereira, M.A., Sobreira, E.T., Bergamaschi, M.M., dos Santos, A.C., Teixeira, A.L., Hallak, J.E., Crippa, J.A., Effects of cannabidiol in the treatment of patients with Parkinson's disease: an exploratory double-blind trial. J. Psychopharmacol. 28 (2014), 1088–1098.
39. Chaouloff, F., Dubreucq, S., Bellocchio, L., Marsicano, G., Endocannabinoids and motor behavior: CB1 receptors also control running activity. Physiology 26 (2011), 76–77.
40. Chen, R., Zhang, J., Wu, Y., Wang, D., Feng, G., Tang, Y.P., Teng, Z., Chen, C., Monoacylglycerol lipase is a therapeutic target for Alzheimer's disease. Cell Rep. 2 (2012), 1329–1339.
41. Chiarlone, A., Bellocchio, L., Blázquez, C., Resel, E., Soria-Gómez, E., Cannich, A., Ferrero, J.J., Sagredo, O., Benito, C., Romero, J., Sánchez-Prieto, J., Lutz, B., Fernández-Ruiz, J., Galve-Roperh, I., Guzmán, M., A restricted population of CB1 cannabinoid receptors with neuroprotective activity. Proc. Natl. Acad. Sci. U. S. A. 11122 (2014), 8257–8262.
42. Chicca, A., Arena, C., Manera, C., Beyond the direct activation of cannabinoid receptors: new strategies to modulate the endocannabinoid system in CNS-Related diseases. Recent Patents CNS Drug Discov. 10 (2015), 122–141.
43. Chicca, A., Nicolussi, S., Bartholomäus, R., Blunder, M., Aparisi Rey, A., Petrucci, V., Reynoso-Moreno, I.D.C., Viveros-Paredes, J.M., Dalghi Gens, M., Lutz, B., Schiöth, H.B., Soeberdt, M., Abels, C., Charles, R.P., Altmann, K.H., Gertsch, J., Chemical probes to potently and selectively inhibit endocannabinoid cellular reuptake. Proc. Natl. Acad. Sci. U. S. A. 114 (2017), E5006–E5015.
44. Chiurchiù V., Cencioni, M.T., Bisicchia, E., De Bardi, M., Gasperini, C., Borsellino, G., Centonze, D., Battistini, L., Maccarrone, M., Distinct modulation of human myeloid and plasmacytoid dendritic cells by anandamide in multiple sclerosis. Ann. Neurol. 73 (2013), 626–636.
45. Chiurchiù V., Leuti, A., Maccarrone, M., Cannabinoid signaling and neuroinflammatory diseases: a melting pot for the regulation of brain immune responses. J. Neuroimmune Pharmacol. 10 (2015), 268–280.
46. Chiurchiù V., Battistini, L., Maccarrone, M., Endocannabinoid signaling in innate and adaptive immunity. Immunology 144 (2015), 352–364.
47. Chiurchiù V., Novel targets in multiple sclerosis: to oxidative stress and beyond. Curr. Top Med. Chem. 14 (2014), 2590–2599.
48. Chung, Y.C., Shin, W.H., Baek, J.Y., Cho, E.J., Baik, H.H., Kim, S.R., Won, S.Y., Jin, B.K., CB2 receptor activation prevents glial-derived neurotoxic mediator production, BBB leakage and peripheral immune cell infiltration and rescues dopamine neurons in the MPTP model of Parkinson's disease. Exp. Mol. Med., 481, 2016, e205.
49. Coghe, G., Pau, M., Corona, F., Frau, J., Lorefice, L., Fenu, G., Spinicci, G., Mamusa, E., Musu, L., Massole, S., Massa, R., Marrosu, M.G., Cocco, E., Walking improvements with nabiximols in patients with multiple sclerosis. J. Neurol. 262 (2015), 2472–2477.
50. Compston, A., Coles, A., Multiple sclerosis. Lancet 372 (2008), 1502–1517.
51. Concannon, R.M., Okine, B.N., Finn, D.P., Dowd, E., Differential upregulation of the cannabinoid CB₂ receptor in neurotoxic and inflammation-driven rat models of Parkinson's disease. Exp. Neurol. 269 (2015), 133–141.
52. Consroe, P., Laguna, J., Allender, J., Snider, S., Stern, L., Sandyk, R., Kennedy, K., Schram, K., Controlled clinical trial of cannabidiol in Huntington's disease. Pharmacol. Biochem. Behav. 40 (1991), 701–708.
53. Correa, F., Hernangómez-Herrero, M., Mestre, L., Loría, F., Docagne, F., Guaza, C., The endocannabinoid anandamide downregulates IL-23 and IL-12 subunits in aviral model of multiple sclerosis: evidence for a cross- talk between IL-12p70/IL-23 axis and IL-10 in microglial cells. Brain Behav. Immun. 25 (2011), 736–749.
54. Cravatt, B.F., Giang, D.K., Mayfield, S.P., Boger, D.L., Lerner, R.A., Gilula, N.B., Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384 (1996), 83–87.
55. Crotti, A., Glass, C.K., The choreography of neuroinflammation in Huntington's disease. Trends Immunol. 366 (2015), 364–373.
56. Croxford, J.L., Miller, S.D., Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R + WIN55, 212. J. Clin. Invest. 111 (2003), 1231–1240.
57. Curtis, A., Mitchell, I., Patel, S., Ives, N., Rickards, H., A pilot study using nabilone for symptomatic treatment in Huntington's disease. Mov. Disord. 24 (2009), 2254–2259.
58. D'Addario, C., Di Francesco, A., Arosio, B., Gussago, C., Dell'osso, B., Bari, M., Galimberti, D., Scarpini, E., Altamura, A.C., Mari, D., Maccarrone, M., Epigenetic regulation of fatty acid amide hydrolase in Alzheimer disease. PLoS One, 7, 2012, e39186.
59. D'Addario, C., Di Francesco, A., Pucci, M., Finazzi Agrò A., Maccarrone, M., Epigenetic mechanisms and endocannabinoid signalling. FEBS J. 2809 (2013), 1905–1917.
60. De Chiara, V., Errico, F., Musella, A., Rossi, S., Mataluni, G., Sacchetti, L., Siracusano, A., Castelli, M., Cavasinni, F., Bernardi, G., Usiello, A., Centonze, D., Voluntary exercise and sucrose consumption enhance cannabinoid CB1 receptor sensitivity in the striatum. Neuropsychopharmacology 35 (2010), 374–387.
61. De Virgilio, A., Greco, A., Fabbrini, G., Inghilleri, M., Rizzo, M.I., Gallo, A., Conte, M., Rosato, C., Appiani, M., de Vincentiis, M., Parkinson's disease: autoimmunity and neuroinflammation. Autoimmun. Rev. 1510 (2016), 1005–1011.
62. Devane, W.A., Dysarz, F.A. 3rd, Johnson, M.R., Melvin, L.S., Howlett, A.C., Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol. 34 (1988), 605–613.
63. Di Filippo, M., Pini, L.A., Pelliccioli, G.P., Calabresi, P., Sarchielli, P., Abnormalities in the cerebrospinal fluid levels of endocannabinoids in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 79 (2008), 1224–1229.
64. Di Marzo, V., Fontana, A., Cadas, H., Schinelli, S., Cimino, G., Schwartz, J.C., Piomelli, D., Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 372 (1994), 686–691.
65. Di Marzo, V., Stella, N., Zimmer, A., Endocannabinoid signalling and the deteriorating brain. Nat. Rev. Neurosci. 16 (2015), 30–42.
66. Dinh, T.P., Carpenter, D., Leslie, F.M., Freund, T.F., Katona, I., Sensi, S.L., Kathuria, S., Piomelli, D., Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc. Natl. Acad. Sci. U. S. A. 99 (2002), 10819–10824.
67. Dubreucq, S., Durand, A., Matias, I., Bénard, G., Richard, E., Soria-Gomez, E., Glangetas, C., Groc, L., Wadleigh, A., Massa, F., Bartsch, D., Marsicano, G., Georges, F., Chaouloff, F., Ventral tegmental area cannabinoid type-1 receptors control voluntary exercise performance. Biol. Psychiatry 73 (2013), 895–903.
68. Dutta, R., Trapp, B.D., Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis. Prog. Neurobiol. 93 (2011), 1–12.
69. Eljaschewitsch, E., Witting, A., Mawrin, C., Lee, T., Schmidt, P.M., Wolf, S., Hoertnagl, H., Raine, C.S., Schneider-Stock, R., Nitsch, R., Ullrich, O., The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. Neuron 49 (2006), 67–79.
70. Esposito, G., Scuderi, C., Savani, C., Steardo, L. Jr., De Filippis, D., Cottone, P., Iuvone, T., Cuomo, V., Steardo, L., Cannabidiol in vivo blunts beta-amyloid induced neuroinflammation by suppressing IL-1beta and iNOS expression. Br. J. Pharmacol. 151 (2007), 1272–1279.
71. Eubanks, L.M., Rogers, C.J., Beuscher, A.E., Koob, G.F., Olson, A.J., Dickerson, T.J., Janda, K.D., A molecular link between the active component of marijuana and Alzheimer's disease pathology. Mol. Pharm. 3 (2006), 773–777.
72. Feinstein, A., Dalgas, U., The benefits of exercise in progressive MS: some cautious optimism. Mult. Scler. 20 (2014), 269–270.
73. Feinstein, A., Freeman, J., Lo, A.C., Treatment of progressive multiple sclerosis: what works, what does not, and what is needed. Lancet Neurol. 14 (2015), 194–207.
74. ®) -like combination of phytocannabinoids as a disease-modifying therapy in a viral model of multiple sclerosis. Br. J. Pharmacol. 172 (2015), 3579–3595.
75. Fernández-Ruiz, J., Romero, J., Ramos, J.A., Endocannabinoids and neurodegenerative disorders: parkinson's disease, Huntington's chorea, Alzheimer's disease, and others. Handb. Exp. Pharmacol. 231 (2015), 233–259.
76. Ferreira-Vieira, T.H., Bastos, C.P., Pereira, G.S., Moreira, F.A., Massensini, A.R., A role for the endocannabinoid system in exercise-induced spatial memory enhancement in mice. Hippocampus 24 (2014), 79–88.
77. Fraussen, J., de Bock, L., Somers, V., B cells and antibodies in progressive multiple sclerosis: contribution to neurodegeneration and progression. Autoimmun. Rev. 15 (2016), 896–899.
78. Galdino, G., Romero, T.R., Silva, J.F., Aguiar, D.C., de Paula, A.M., Cruz, J.S., Parrella, C., Piscitelli, F., Duarte, I.D., Di Marzo, V., Perez, A.C., The endocannabinoid system mediates aerobic exercise-induced antinociception in rats. Neuropharmacology 77 (2014), 313–324.
79. Galve-Roperh, I., Chiurchiù V., Díaz-Alonso, J., Bari, M., Guzmán, M., Maccarrone, M., Cannabinoid receptor signaling in progenitor/stem cell proliferation and differentiation. Prog. Lipid Res. 52 (2013), 633–650.
80. Gandhi, R., Laroni, A., Weiner, H.L., Role of the innate immune system in the pathogenesis of multiple sclerosis. J. Neuroimmunol. 221 (2010), 7–14.
81. Gaoni, Y., Mechoulam, R., Isolation, structure and partial synthesis of an active constituent of hashish. J. Am. Chem. Soc. 86 (1964), 1646–1647.
82. Giacoppo, S., Soundara Rajan, T., Galuppo, M., Pollastro, F., Grassi, G., Bramanti, P., Mazzon, E., Purified Cannabidiol, the main non-psychotropic component of Cannabis sativa, alone, counteracts neuronal apoptosis in experimental multiple sclerosis. Eur. Rev. Med. Pharmacol. Sci. 1924 (2015), 4906–4919.
83. Giacoppo, S., Pollastro, F., Grassi, G., Bramanti, P., Mazzon, E., Target regulation of PI3K/Akt/mTOR pathway by cannabidiol in treatment of experimental multiple sclerosis. Fitoterapia 116 (2017), 77–84.
84. Gloss, D., Vickrey, B., Cannabinoids for epilepsy. Cochrane Database Syst. Rev., 3, 2014, CD009270.
85. Gonzalez, S., Scorticati, C., Garcia-Arencibia, M., de Miguel, R., Ramos, J.A., Fernandez-Ruiz, J., Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease. Brain Res. 1073–1074 (2006), 209–219.
86. Gosselet, F., Saint-Pol, J., Candela, P., Fenart, L., Amyloid-beta peptides, Alzheimer's disease and the blood-brain barrier. Curr. Alzheimer Res. 10 (2013), 1015–1033.
87. Gubellini, P., Picconi, B., Bari, M., Battista, N., Calabresi, P., Centonze, D., Bernardi, G., Finazzi-Agrò A., Maccarrone, M., Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission. J. Neurosci. 2216 (2002), 6900–6907.
88. Hafler, D.A., Compston, A., Sawcer, S., Lander, E.S., Daly, M.J., De Jager, P.L., de Bakker, P.I., Gabriel, S.B., Mirel, D.B., Ivinson, A.J., Pericak-Vance, M.A., Gregory, S.G., Rioux, J.D., McCauley, J.L., Haines, J.L., Barcellos, L.F., Cree, B., Oksenberg, J.R., Hauser, S.L., (International Multiple Sclerosis Genetics Consortium), Risk alleles for multiple sclerosis identified by a genomewide study. N. Engl. J. Med. 357 (2007), 851–862.
89. Harbo, H.F., Gold, R., Tintoré M., Sex and gender issues in multiple sclerosis. Ther. Adv. Neurol. Disord. 64 (2013), 237–248.
90. Hernández-Torres, G., Cipriano, M., Hedén, E., Björklund, E., Canales, Á., Zian, D., Feliú A., Mecha, M., Guaza, C., Fowler, C.J., Ortega-Gutiérrez, S., López-Rodríguez, M.L., A reversible and selective inhibitor of monoacylglycerol lipase ameliorates multiple sclerosis. Angew. Chem. Int. Ed. Engl. 53 (2014), 13765–13770.
91. Hernangómez, M., Mestre, L., Correa, F.G., Loría, F., Mecha, M., Iñigo, P.M., Docagne, F., Williams, R.O., Borrell, J., Guaza, C., CD200-CD200R1 interaction contributes to neuroprotective effects of anandamide on experimentally induced inflammation. Glia 60 (2012), 1437–1450.
92. Hernangómez, M., Carrillo-Salinas, F.J., Mecha, M., Correa, F., Mestre, L., Loría, F., Feliú A., Docagne, F., Guaza, C., Brain innate immunity in the regulation of neuroinflammation: therapeutic strategies by modulating CD200-CD200R interaction involve the cannabinoid system. Curr. Pharm. Des. 20 (2014), 4707–4722.
93. Horne, E.A., Coy, J., Swinney, K., Fung, S., Cherry, A.E., Marrs, W.R., Naydenov, A.V., Lin, Y.H., Sun, X., Keene, C.D., Grouzmann, E., Muchowski, P., Bates, G.P., Mackie, K., Stella, N., Downregulation of cannabinoid receptor 1 from neuropeptide Y interneurons in the basal ganglia of patients with Huntington's disease and mouse models. Eur. J. Neurosci. 37 (2013), 429–440.
94. Huffman, J.W., The search for selective ligands for the CB2 receptor. Curr. Pharm. Des. 613 (2000), 1323–1337.
95. Huynh, J.L., Casaccia, P., Epigenetic mechanisms in multiple sclerosis: implications for pathogenesis and treatment. Lancet Neurol. 12 (2013), 195–206.
96. Jackson, S.J., Diemel, L.T., Pryce, G., Baker, D., Cannabinoids and neuroprotection in CNS inflammatory disease. J. Neurol. Sci. 233 (2005), 21–25.
97. Javed, H., Azimullah, S., Haque, M.E., Ojha, S.K., Cannabinoid type 2 CB2 receptors activation protects against oxidative stress and neuroinflammation associated dopaminergic neurodegeneration in rotenone model of parkinson's disease. Front. Neurosci., 10, 2016, 321.
98. Jean-Gilles, L., Feng, S., Tench, C.R., Chapman, V., Kendall, D.A., Barrett, D.A., Constantinescu, C.S., Plasma endocannabinoid levels in multiple sclerosis. J. Neurol. Sci. 287 (2009), 212–215.
99. Jensen, C.J., Massie, A., De Keyser, J., Immune players in the CNS: the astrocyte. J. Neuroimmune Pharmacol. 8 (2013), 824–839.
100. Joerger, M., Wilkins, J., Fagagnini, S., Baldinger, R., Brenneisen, R., Schneider, U., Goldman, B., Weber, M., Single-dose pharmacokinetics and tolerability of oral delta-9- tetrahydrocannabinol in patients with amyotrophic lateral sclerosis. Drug Metab. Lett. 6 (2012), 102–108.
101. Jung, K.M., Astarita, G., Yasar, S., Vasilevko, V., Cribbs, D.H., Head, E., Cotman, C.W., Piomelli, D., An amyloid β42-dependent deficit in anandamide mobilization is associated with cognitive dysfunction in Alzheimer's disease. Neurobiol. Aging 33 (2012), 1522–1532.
102. Kassmann, C.M., Lappe-Siefke, C., Baes, M., Brügger, B., Mildner, A., Werner, H.B., Natt, O., Michaelis, T., Prinz, M., Frahm, J., Nave, K.A., Axonal loss and neuroinflammation caused by peroxisome-deficient oligodendrocytes. Nat. Genet. 39 (2007), 969–976.
103. Katona, S., Kaminski, E., Sanders, H., Zajicek, J., Cannabinoid influence on cytokine profile in multiple sclerosis. Clin. Exp. Immunol. 140 (2005), 580–585.
104. Kerbrat, A., Ferre, J.C., Fillatre, P., Ronziere, T., Vannier, S., Carsin-Nicol, B., Lavoue, S., Verin, M., Gauvrit, J.Y., Le Tulzo, Y., Edan, G., Acute Neurologic distorder froma an inhibitor of fatty acid amide hydrolase. N. Engl. J. Med. 375 (2016), 1717–1725.
105. Kiernan, M.C., Vucic, S., Cheah, B.C., Turner, M.R., Eisen, A., Hardiman, O., Burrell, J.R., Zoing, M.C., Amyotrophic lateral sclerosis. Lancet 377 (2011), 942–955.
106. Killestein, J., Hoogervorst, E.L., Reif, M., Blauw, B., Smits, M., Uitdehaag, B.M., Nagelkerken, L., Polman, C.H., Immunomodulatory effects of orally administered cannabinoids in multiple sclerosis. J. Neuroimmunol. 137 (2003), 140–143.
107. Kim, K., Moore, D.H., Makriyannis, A., Abood, M.E., AM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis. Eur. J. Pharmacol. 542 (2006), 100–105.
108. Kong, W., Li, H., Tuma, R.F., Ganea, D., Selective CB2 receptor activation ameliorates EAE by reducing Th17 differentiation and immune cell accumulation in the CNS. Cell. Immunol. 287 (2014), 1–17.
109. Koppel, B.S., Brust, J.C., Fife, T., Bronstein, J., Youssof, S., Gronseth, G., Gloss, D., Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 82 (2014), 1556–1563.
110. Kozela, E., Lev, N., Kaushansky, N., Eilam, R., Rimmerman, N., Levy, R., Ben-Nun, A., Juknat, A., Vogel, Z., Cannabidiol inhibits pathogenic T cells, decreases spinal microglial activation and ameliorates multiple sclerosis-like disease in C57BL/6 mice. Br. J. Pharmacol. 1637 (2011), 1507–1519.
111. Kozela, E., Juknat, A., Gao, F., Kaushansky, N., Coppola, G., Vogel, Z., Pathways and gene networks mediating the regulatory effects of cannabidiol, a nonpsychoactive cannabinoid, in autoimmune T cells. J. Neuroinflammation, 13, 2016, 136.
112. López-Sendón Moreno, J.L., García Caldentey, J., Trigo Cubillo, P., Ruiz Romero, C., García Ribas, G., Alonso Arias, M.A., García de Yébenes, M.J., Tolón, R.M., Galve-Roperh, I., Sagredo, O., Valdeolivas, S., Resel, E., Ortega-Gutierrez, S., García-Bermejo, M.L., Fernández Ruiz, J., Guzmán, M., García de Yébenes Prous, J., óA double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington's disease. J. Neurol. 2637 (2016), 1390–1400.
113. Lassmann, H., van Horssen, J., Mahad, D., Progressive multiple sclerosis: pathology and pathogenesis. Nat. Rev. Neurol. 8 (2012), 647–656.
114. Lastres-Becker, I., De Miguel, R., Fernandez-Ruiz, J.J., The endocannabinoid system and Huntington's disease. Curr. Drug. Targets CNS Neurol. Disord. 2 (2003), 335–347.
115. Lastres-Becker, I., Molina-Holgado, F., Ramos, J.A., Mechoulam, R., Fernandez- Ruiz, J., Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease. Neurobiol. Dis. 19 (2005), 96–107.
116. ® and clinical-neurophysiological measures of spasticity in progressive multiple sclerosis. J. Neurol. 262 (2015), 2520–2527.
117. Leterrier, C., Bonnard, D., Carrel, D., Rossier, J., Lenkei, Z., Constitutive endocytic cycle of the CB1 cannabinoid receptor. J. Biol. Chem. 279 (2004), 36013–36021.
118. Leung, D., Saghatelian, A., Simon, G.M., Cravatt, B.F., Inactivation of N-acyl phosphatidylethanolamine phospholipase D reveals multiple mechanisms for the biosynthesis of endocannabinoids. Biochemistry 45 (2006), 4720–4726.
119. Li, G.L., Winter, H., Arends, R., Jay, G.W., Le, V., Young, T., Huggins, J.P., Assessment of the pharmacology and tolerability of PF-04457845, an irreversible inhibitor of fatty acid amide hydrolase-1, in healthy subjects. Br. J. Clin. Pharmacol. 73 (2012), 706–716.
120. Liu, J., Wang, L., Harvey-White, J., Osei-Hyiaman, D., Razdan, R., Gong, Q., Chan, A.C., Zhou, Z., Huang, B.X., Kim, H.Y., Kunos, G., A biosynthetic pathway for anandamide. Proc. Natl. Acad. Sci. U. S. A. 103 (2006), 13345–13350.
121. Loría, F., Petrosino, S., Mestre, L., Spagnolo, A., Correa, F., Hernangómez, M., Guaza, C., Di Marzo, V., Docagne, F., Study of the regulation of the endocannabinoid system in a virus model of multiple sclerosis reveals a therapeutic effect of palmitoylethanolamide. Eur. J. Neurosci. 28 (2008), 633–641.
122. Loría, F., Petrosino, S., Hernangómez, M., Mestre, L., Spagnolo, A., Correa, F., Di Marzo, V., Docagne, F., Guaza, C., An endocannabinoid tone limits excitotoxicity in vitro and in a model of multiple sclerosis. Neurobiol. Dis. 37 (2010), 166–176.
123. Lourbopoulos, A., Grigoriadis, N., Lagoudaki, R., Touloumi, O., Polyzoidou, E., Mavromatis, I., Tascos, N., Breuer, A., Ovadia, H., Karussis, D., Shohami, E., Mechoulam, R., Simeonidou, C., Administration of 2-arachidonoylglycerol ameliorates both acute and chronic experimental autoimmune encephalomyelitis. Brain Res. 1390 (2011), 126–141.
124. Lublin, F.D., Reingold, S.C., Cohen, J.A., Cutter, G.R., Sørensen, P.S., Thompson, A.J., Wolinsky, J.S., Balcer, L.J., Banwell, B., Barkhof, F., Bebo, B. Jr., Calabresi, P.A., Clanet, M., Comi, G., Fox, R.J., Freedman, M.S., Goodman, A.D., Inglese, M., Kappos, L., Kieseier, B.C., Lincoln, J.A., Lubetzki, C., Miller, A.E., Montalban, X., O'Connor, P.W., Petkau, J., Pozzilli, C., Rudick, R.A., Sormani, M.P., Stüve, O., Waubant, E., Polman, C.H., Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 83 (2014), 278–286.
125. Lucanic, M., Held, J.M., Vantipalli, M.C., Klang, I.M., Graham, J.B., Gibson, B.W., Lithgow, G.J., Gill, M.S., N-acylethanolamine signalling mediates the effect of diet on lifespan in Caenorhabditis elegans. Nature 473 (2011), 226–229.
126. Maccarrone, M., Dainese, E., Oddi, S., Intracellular trafficking of anandamide: new concepts for signaling. Trends Biochem. Sci. 35 (2010), 601–608.
127. Maccarrone, M., Guzmán, M., Mackie, K., Doherty, P., Harkany, T., Programming of neural cells by endocannabinoids: from physiological rules to emerging therapies. Nat. Rev. Neurosci. 15 (2014), 786–801.
128. Maccarrone, M., Bab, I., Bíró T., Cabral, G.A., Dey, S.K., Di Marzo, V., Konje, J.C., Kunos, G., Mechoulam, R., Pacher, P., Sharkey, K.A., Zimmer, A., Endocannabinoid signaling at the periphery: 50 years after THC. Trends Pharmacol. Sci. 36 (2015), 277–296.
129. Maccarrone, M., Maldonado, R., Casas, M., Henze, T., Centonze, D., Cannabinoids therapeutic use: what is our current understanding following the introduction of THC, THC:CBD oromucosal spray and others?. Exp. Rev. Clin. Pharmacol. 10 (2017), 443–455.
130. Mahad, D.H., Trapp, B.D., Lassmann, H., Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol. 14 (2015), 183–193.
131. Mahadevan, A., Siegel, C., Martin, B.R., Abood, M.E., Beletskaya, I., Razdan, R.K., Novel cannabinol probes for CB1 and CB2 cannabinoid receptors. J. Med. Chem. 4320 (2000), 3778–3785.
132. Malfitano, A.M., Laezza, C., D'Alessandro, A., Procaccini, C., Saccomanni, G., Tuccinardi, T., Manera, C., Macchia, M., Matarese, G., Gazzerro, P., Bifulco, M., Effects on immune cells of a new 1, 8-naphthyridin-2-one derivative and its analogues as selective CB2 agonists: implications in multiple sclerosis. PLoS One, 8, 2013, e62511.
133. Mandolesi, G., Gentile, A., Musella, A., Fresegna, D., De Vito, F., Bullitta, S., Sepman, H., Marfia, G.A., Centonze, D., Synaptopathy connects inflammation and neurodegeneration in multiple sclerosis. Nat. Rev. Neurol. 11 (2015), 711–724.
134. Maresz, K., Pryce, G., Ponomarev, E.D., Marsicano, G., Croxford, J.L., Shriver, L.P., Ledent, C., Cheng, X., Carrier, E.J., Mann, M.K., Giovannoni, G., Pertwee, R.G., Yamamura, T., Buckley, N.E., Hillard, C.J., Lutz, B., Baker, D., Dittel, B.N., Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. Nat. Med. 13 (2007), 492–497.
135. Marsicano, G., Goodenough, S., Monory, K., Hermann, H., Eder, M., Cannich, A., Azad, S.C., Cascio, M.G., Gutiérrez, S.O., van der Stelt, M., López-Rodriguez, M.L., Casanova, E., Schütz, G., Zieglgänsberger, W., Di Marzo, V., Behl, C., Lutz, B., CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 302 (2003), 84–88.
136. Martín-Moreno, A.M., Brera, B., Spuch, C., Carro, E., García-García, L., Delgado, M., Pozo, M.A., Innamorato, N.G., Cuadrado, A., de Ceballos, M.L., Prolonged oral cannabinoid administration prevents neuroinflammation, lowers β-amyloid levels and improves cognitive performance in Tg APP 2576 mice. J. Neuroinflammation, 9, 2012, 8.
137. Mazzola, C., Micale, V., Drago, F., Amnesia induced by beta-amyloid fragments is counteracted by cannabinoid CB1 receptor blockade. Eur. J. Pharmacol. 477 (2003), 219–225.
138. Mecha, M., Torrao, A.S., Mestre, L., Carrillo-Salinas, F.J., Mechoulam, R., Guaza, C., Cannabidiol protects oligodendrocyte progenitor cells from inflammation-induced apoptosis by attenuating endoplasmic reticulum stress. Cell. Death. Dis., 3, 2012, e331.
139. Mecha, M., Feliú A., Iñigo, P.M., Mestre, L., Carrillo-Salinas, F.J., Guaza, C., Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: a role for A2A receptors. Neurobiol. Dis. 59 (2013), 141–150.
140. Mecha, M., Feliú A., Carrillo-Salinas, F.J., Rueda-Zubiaurre, A., Ortega-Gutiérrez, S., de Sola, R.G., Guaza, C., Endocannabinoids drive the acquisition of an alternative phenotype in microglia. Brain. Behav. Immun. 49 (2015), 233–245.
141. Mecha, M., Carrillo-Salinas, F.J., Feliú A., Mestre, L., Guaza, C., Microglia activation states and cannabinoid system: therapeutic implications. Pharmacol. Ther. 166 (2016), 40–55.
142. Mechoulam, R., Feigenbaum, J.J., Lander, N., Segal, M., Järbe, T.U., Hiltunen, A.J., Consroe, P., Enantiomeric cannabinoids: stereospecificity of psychotropic activity. Experientia 44 (1988), 762–764.
143. Mechoulam, R., Peters, M., Murillo-Rodriguez, E., Hanus, L.O., Cannabidiol–recent advances. Chem. Biodivers. 48 (2007), 1678–1692.
144. Mechoulam, R., Hanuš L.O., Pertwee, R., Howlett, A.C., Early phytocannabinoid chemistry to endocannabinoids and beyond. Nat. Rev. Neurosci. 15 (2014), 757–764.
145. Mestre, L., Correa, F., Arévalo-Martín, A., Molina-Holgado, E., Valenti, M., Ortar, G., Di Marzo, V., Guaza, C., Pharmacological modulation of the endocannabinoid system in a viral model of multiple sclerosis. J. Neurochem. 92 (2005), 1327–1339.
146. Mestre, L., Docagne, F., Correa, F., Loría, F., Hernangómez, M., Borrell, J., Guaza, C., A cannabinoid agonist interferes with the progression of a chronic model of multiple sclerosis by downregulating adhesion molecules. Mol. Cell Neurosci. 40 (2009), 258–266.
147. Montalban, X., Hauser, S.L., Kappos, L., Arnold, D.L., Bar-Or, A., Comi, G., de Seze, J., Giovannoni, G., Hartung, H.P., Hemmer, B., Lublin, F., Rammohan, K.W., Selmaj, K., Traboulsee, A., Sauter, A., Masterman, D., Fontoura, P., Belachew, S., Garren, H., Mairon, N., Chin, P., Wolinsky, J.S., ORATORIO Clinical Investigators, Ocrelizumab versus placebo in primary progressive multiple sclerosis. N. Engl. J. Med. 376 (2017), 209–220.
148. ®-like combination of phytocannabinoids: interest for future therapies in amyotrophic lateral sclerosis. CNS Neurosci. Ther. 20 (2014), 809–815.
149. Moreno-Martet, M., Feliú A., Espejo-Porras, F., Mecha, M., Carrillo-Salinas, F.J., Fernández-Ruiz, J., Guaza, C., de Lago, E., The disease-modifying effects of a Sativex-like combination of phytocannabinoids in mice with experimental autoimmune encephalomyelitis are preferentially due to Δ9-tetrahydrocannabinol acting through CB1 receptors. Mult. Scler. Relat. Disord. 4 (2015), 505–511.
150. Moriconi, A., Cerbara, I., Maccarrone, M., Topai, A., GPR55: Current knowledge and future perspectives of a purported Type-3 cannabinoid receptor. Curr. Med. Chem. 17 (2010), 1411–1429.
151. Mosser, C.A., Baptista, S., Arnoux, I., Audinat, E., Microglia in CNS development: shaping the brain for the future. Prog. Neurobiol. 149–150 (2017), 1–20.
152. Mounsey Mustafa, R.B.S., Robinson, L., Ross, R.A., Riedel, G., Pertwee, R.G., Teismann, P., Increasing levels of the endocannabinoid 2-AG is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Exp. Neurol. 273 (2015), 36–44.
153. Munro, S., Thomas, K.L., Abu-Shaar, M., Molecular characterization of a peripheral receptor for cannabinoids. Nature 365 (1993), 61–65.
154. Musella, A., Sepman, H., Mandolesi, G., Gentile, A., Fresegna, D., Haji, N., Conrad, A., Lutz, B., Maccarrone, M., Centonze, D., Pre- and postsynaptic type-1 cannabinoid receptors control the alterations of glutamate transmission in experimental autoimmune encephalomyelitis. Neuropharmacology 79 (2014), 567–572.
155. Musella, A., Mandolesi, G., Mori, F., Gentile, A., Centonze, D., Linking synaptopathy and gray matter damage in multiple sclerosis. Mult. Scler. 22 (2016), 146–149.
156. Musumeci, G., Grasselli, G., Rossi, S., De Chiara, V., Musella, A., Motta, C., Studer, V., Bernardi, G., Haji, N., Sepman, H., Fresegna, D., Maccarrone, M., Mandolesi, G., Centonze, D., Transient receptor potential vanilloid 1 channels modulate the synaptic effectsof TNF-α and of IL-1β in experimental autoimmune encephalomyelitis. Neurobiol. Dis. 43 (2011), 669–677.
157. Navarrete, M., Araque, A., Endocannabinoids potentiate synaptic transmission through stimulation of astrocytes. Neuron 68 (2010), 113–126.
158. Nayak, D., Roth, T.L., McGavern, D.B., Microglia development and function. Annu. Rev. Immunol. 32 (2014), 367–402.
159. Nomura, D.K., Morrison, B.E., Blankman, J.L., Long, J.Z., Kinsey, S.G., Marcondes, M.C., Ward, A.M., Hahn, Y.K., Lichtman, A.H., Conti, B., Cravatt, B.F., Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. Science 334 (2011), 809–813.
160. Ogasawara, D., Deng, H., Viader, A., Baggelaar, M.P., Breman, A., den Dulk, H., van den Nieuwendijk, A.M., Soethoudt, M., van der Wel, T., Zhou, J., Overkleeft, H.S., Sanchez-Alavez, M., Mori, S., Nguyen, W., Conti, B., Liu, X., Chen, Y., Liu, Q.S., Cravatt, B.F., van der Stelt, M., Rapid and profound rewiring of brain lipid signaling networks by acute diacylglycerol lipase inhibition. Proc. Natl. Acad. Sci. U. S. A. 113 (2016), 26–33.
161. Ohno-Shosaku, T., Maejima, T., Kano, M., Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals. Neuron 29 (2001), 729–738.
162. Okamoto, Y., Morishita, J., Tsuboi, K., Tonai, T., Ueda, N., Molecular characterization of a phospholipase D generating anandamide and its congeners. J. Biol. Chem. 279 (2004), 5298–5305.
163. Onaivi, E.S., Ishiguro, H., Gong, J.P., Patel, S., Perchuk, A., Meozzi, P.A., Myers, L., Mora, Z., Tagliaferro, P., Gardner, E., Brusco, A., Akinshola, B.E., Liu, Q.R., Hope, B., Iwasaki, S., Arinami, T., Teasenfitz, L., Uhl, G.R., Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. Ann. N. Y. Acad. Sci. 1074 (2006), 514–536.
164. Ortega-Gutiérrez, S., Molina-Holgado, E., Arévalo-Martín, A., Correa, F., Viso, A., López-Rodríguez, M.L., Di Marzo, V., Guaza, C., Activation of the endocannabinoid system as therapeutic approach in a murine model of multiple sclerosis. FASEB J. 19 (2005), 1338–1340.
165. Palazuelos, J., Davoust, N., Julien, B., Hatterer, E., Aguado, T., Mechoulam, R., Benito, C., Romero, J., Silva, A., Guzmán, M., Nataf, S., Galve-Roperh, I., The CB2 cannabinoid receptor controls myeloid progenitor trafficking: involvement in the pathogenesis of an animal model of multiple sclerosis. J. Biol. Chem. 283 (2008), 13320–13329.
166. Palazuelos, J., Aguado, T., Pazos, M.R., Julien, B., Carrasco, C., Resel, E., Sagredo, O., Benito, C., Romero, J., Azcoitia, I., Fernández-Ruiz, J., Guzmán, M., Galve-Roperh, I., Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity. Brain 132 (2009), 3152–3164.
167. Panikashvili, D., Simeonidou, C., Ben-Shabat, S., Hanus, L., Breuer, A., Mechoulam, R., Shohami, E., An endogenous cannabinoid 2-AG is neuroprotective after brain injury. Nature 413 (2001), 527–531.
168. Peferoen, L., Kipp, M., van der Valk, P., van Noort, J.M., Amor, S., Oligodendrocyte-microglia cross-talk in the central nervous system. Immunology 1413 (2014), 302–313.
169. Piro, J.R., Benjamin, D.I., Duerr, J.M., Pi, Y., Gonzales, C., Wood, K.M., Schwartz, J.W., Nomura, D.K., Samad, T.A., A dysregulated endocannabinoid-eicosanoid network supports pathogenesis in a mouse model of Alzheimer's disease. Cell Rep. 1 (2012), 617–623.
170. Pisani, V., Madeo, G., Tassone, A., Sciamanna, G., Maccarrone, M., Stanzione, P., Pisani, A., Homeostatic changes of the endocannabinoid system in Parkinson's disease. Mov. Disord. 26 (2011), 216–222.
171. Pistis, M., Melis, M., From surface to nuclear receptors: the endocannabinoid family extends its assets. Curr. Med. Chem. 17 (2010), 1450–1467.
172. Polman, C.H., Reingold, S.C., Banwell, B., Clanet, M., Cohen, J.A., Filippi, M., Fujihara, K., Havrdova, E., Hutchinson, M., Kappos, L., Lublin, F.D., Montalban, X., O'Connor, P., Sandberg-Wollheim, M., Thompson, A.J., Waubant, E., Weinshenker, B., Wolinsky, J.S., Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann. Neurol. 692 (2011), 292–302.
173. Price, D.A., Martinez, A.A., Seillier, A., Koek, W., Acosta, Y., Fernandez, E., Strong, R., Lutz, B., Marsicano, G., Roberts, J.L., Giuffrida, A., WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Eur. J. Neurosci. 29 (2009), 2177–2186.
174. Pryce, G., Baker, D., Control of spasticity in a multiple sclerosis model is mediated by CB1, not CB2, cannabinoid receptors. Br. J. Pharmacol. 150 (2007), 519–525.
175. Pryce, G., Ahmed, Z., Hankey, D.J., Jackson, S.J., Croxford, J.L., Pocock, J.M., Ledent, C., Petzold, A., Thompson, A.J., Giovannoni, G., Cuzner, M.L., Baker, D., Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain 126 (2003), 2191–2202.
176. Pryce, G., Cabranes, A., Fernández-Ruiz, J., Bisogno, T., Di Marzo, V., Long, J.Z., Cravatt, B.F., Giovannoni, G., Baker, D., Control of experimental spasticity by targeting the degradation of endocannabinoids using selective fatty acid amide hydrolase inhibitors. Mult. Scler. 19 (2013), 1896–1904.
177. Pryce, G., Riddall, D.R., Selwood, D.L., Giovannoni, G., Baker, D., Neuroprotection in experimental autoimmune encephalomyelitis and progressive multiple sclerosis by cannabis-based cannabinoids. J. Neuroimmune Pharmacol. 102 (2015), 281–292.
178. Rahimi, A., Faizi, M., Talebi, F., Noorbakhsh, F., Kahrizi, F., Naderi, N., Interaction between the protective effects of cannabidiol and palmitoylethanolamide in experimental model of multiple sclerosis in C57BL/6 mice. Neuroscience 290 (2015), 279–287.
179. Raman, C., McAllister, S.D., Rizvi, G., Patel, S.G., Moore, D.H., Abood, M.E., Amyotrophic lateral sclerosis: delayed disease progression in mice by treatment with a cannabinoid. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 5 (2004), 33–39.
180. Ramil, E., Sánchez, A.J., González-Pérez, P., Rodríguez-Antigüedad, A., Gómez-Lozano, N., Ortiz, P., Arroyo, R., De las Heras, V., Vilches, C., García-Merino, A., The cannabinoid receptor 1 gene CNR1 and multiple sclerosis: an association study in two case-control groups from Spain. Mult. Scler. 16 (2010), 139–146.
181. Ramirez, B.G., Blazquez, C., Gomez del Pulgar, T., Guzman, M., de Ceballos, M.L., Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J. Neurosci. 25 (2005), 1904–1913.
182. Ramirez, S.H., Hasko, J., Skuba, A., Fan, S., Dykstra, H., McCormick, R., Reichenbach, N., Krizbai, I., Mahadevan, A., Zhang, M., Tuma, R., Son, Y.J., Persidsky, Y., Activation of cannabinoid receptor 2 attenuates leukocyte-endothelial cell interactions and blood-brain barrier dysfunction under inflammatory conditions. J. Neurosci. 32 (2012), 4004–4016.
183. Reynolds, R., Roncaroli, F., Nicholas, R., Radotra, B., Gveric, D., Howell, O., The neuropathological basis of clinical progression in multiple sclerosis. Acta Neuropathol. 1222 (2011), 155–170.
184. Rodríguez, M.J., Mahy, N., Neuron-microglia interactions in motor neuron degeneration. The inflammatory hypothesis in amyotrophic lateral sclerosis revisited. Curr. Med. Chem. 2342 (2016), 4753–4772.
185. Ross, C.A., Tabrizi, S.J., Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 101 (2011), 83–98.
186. Rossi, S., De Chiara, V., Musella, A., Cozzolino, M., Bernardi, G., Maccarrone, M., Mercuri, N.B., Carri, M.T., Centonze, D., Abnormal sensitivity of cannabinoid CB1 receptors in the striatum of mice with experimental amyotrophic lateral sclerosis. Amyotroph. Later. Scler. 11 (2010), 83–90.
187. Rossi, S., Buttari, F., Studer, V., Motta, C., Gravina, P., Castelli, M., Mantovani, V., De Chiara, V., Musella, A., Fiore, S., Masini, S., Bernardi, G., Maccarrone, M., Bernardini, S., Centonze, D., The (AAT)n repeat of the cannabinoid CB1 receptor gene influences disease progression in relapsing multiple sclerosis. Mult. Scler. 17 (2011), 281–288.
188. Rossi, S., Furlan, R., De Chiara, V., Muzio, L., Musella, A., Motta, C., Studer, V., Cavasinni, F., Bernardi, G., Martino, G., Cravatt, B.F., Lutz, B., Maccarrone, M., Centonze, D., Cannabinoid CB1 receptors regulate neuronal TNF-α effects in experimental autoimmune encephalomyelitis. Brain Behav. Immun. 25 (2011), 1242–1248.
189. Rossi, S., Bozzali, M., Bari, M., Mori, F., Studer, V., Motta, C., Buttari, F., Cercignani, M., Gravina, P., Mastrangelo, N., Castelli, M., Mancino, R., Nucci, C., Sottile, F., Bernardini, S., Maccarrone, M., Centonze, D., Association between a genetic variant of type-1 cannabinoid receptor and inflammatory neurodegeneration in multiple sclerosis. PLoS One, 8, 2013, e82848.
190. Rouzer, C.A., Marnett, L.J., Endocannabinoid oxygenation by cyclooxygenases, lipoxygenases, and cytochromes P450: cross-talk between the eicosanoid and endocannabinoid signaling pathways. Chem. Rev. 111 (2011), 5899–5921.
191. Rozenfeld, R., Devi, L.A., Regulation of CB1 cannabinoid receptor trafficking by the adaptor protein AP-3. FASEB J. 22 (2008), 2311–2322.
192. Sánchez López, A.J., Román-Vega, L., Ramil Tojeiro, E., Giuffrida, A., García-Merino, A., Regulation of cannabinoid receptor gene expression and endocannabinoid levels in lymphocyte subsets by interferon-β: a longitudinal study in multiple sclerosis patients. Clin. Exp. Immunol. 179 (2015), 119–127.
193. Sagredo, O., Pazos, M.R., Valdeolivas, S., Fernandez-Ruiz, J., Cannabinoids: novel medicines for the treatment of Huntington's disease. Recent Pat. CNS Drug Discov. 7 (2012), 41–48.
194. Schapira, A.H., Tolosa, E., Molecular and clinical prodrome of Parkinson disease: implications for treatment. Nat. Rev. Neurol. 6 (2010), 309–317.
195. Schwartz, M., Baruch, K., Breaking peripheral immune tolerance to CNS antigens in neurodegenerative diseases: boosting autoimmunity to fight-off chronic neuroinflammation. J. Autoimmun. 54 (2014), 8–14.
196. Shoemaker, J.L., Seely, K.A., Reed, R.L., Crow, J.P., Prather, P.L., The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset. J. Neurochem. 101 (2007), 87–98.
197. Sieradzan, K.A., Fox, S.H., Hill, M., Dick, J.P., Crossman, A.R., Brotchie, J.M., Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study. Neurology 57 (2001), 2108–2111.
198. Stock, K., Garthe, A., de Almeida Sassi, F., Glass, R., Wolf, S.A., Kettenmann, H., The capsaicin receptor TRPV1 as a novel modulator of neural precursor cell proliferation. Stem Cells 32 (2014), 3183–3195.
199. Stys, P.K., Zamponi, G.W., van Minnen, J., Geurts, J.J., Will the real multiple sclerosis please stand up?. Nat. Rev. Neurosci. 137 (2012), 507–514.
200. Swinnen, B., Robberecht, W., The phenotypic variability of amyotrophic lateral sclerosis. Nat. Rev. Neurol. 1011 (2014), 661–670.
201. Tantimonaco, M., Ceci, R., Sabatini, S., Catani, M.V., Rossi, A., Gasperi, V., Maccarrone, M., Physical activity and the endocannabinoid system: an overview. Cell Mol. Life Sci. 71 (2014), 2681–2698.
202. Tsunoda, I., Fujinami, R.S., Inside-Out versus Outside-In models for virus induced demyelination: axonal damage triggering demyelination. Springer Semin. Immunopathol. 242 (2002), 105–125.
203. Ueda, N., Tsuboi, K., Uyama, T., Metabolism of endocannabinoids and related N-acylethanolamines: canonical and alternative pathways. FEBS J. 280 (2013), 1874–1894.
204. Van Sickle, M.D., Duncan, M., Kingsley, P.J., Mouihate, A., Urbani, P., Mackie, K., Stella, N., Makriyannis, A., Piomelli, D., Davison, J.S., Marnett, L.J., Di Marzo, V., Pittman, Q.J., Patel, K.D., Sharkey, K.A., Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310 (2005), 329–332.
205. Volicer, L., Stelly, M., Morris, J., McLaughlin, J., Volicer, B.J., Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease. Int. J. Geriatr. Psychiatry 12 (1997), 913–919.
206. Walther, S., Mahlberg, R., Eichmann, U., Kunz, D., Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia. Psychopharmacology (Berl.) 185 (2006), 524–528.
207. Webb, M., Luo, L., Ma, J.Y., Tham, C.S., Genetic deletion of fatty acid Amide hydrolase results in improved long-term outcome in chronic autoimmune encephalitis. Neurosci. Lett. 439 (2008), 106–110.
208. Weber, M., Goldman, B., Truniger, S., Tetrahydrocannabinol THC for cramps in amyotrophic lateral sclerosis: a randomised, double-blind crossover trial. J. Neurol. Neurosurg. Psychiatry 81 (2010), 1135–1140.
209. Westlake, T.M., Howlett, A.C., Bonner, T.I., Matsuda, L.A., Herkenham, M., Cannabinoid receptor binding and messenger RNA expression in human brain: an in vitro receptor autoradiography and in situ hybridization histochemistry study of normal aged and Alzheimer's brains. Neuroscience 63 (1994), 637–652.
210. Whiting, P.F., Wolff, R.F., Deshpande, S., Di Nisio, M., Duffy, S., Hernandez, A.V., Keurentjes, J.C., Lang, S., Misso, K., Ryder, S., Schmidlkofer, S., Westwood, M., Kleijnen, J., Cannabinoids for medical use: a systematic review and meta-analysis. JAMA 313 (2015), 2456–2473.
211. Wilson, R.I., Nicoll, R.A., Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature 410 (2001), 588–592.
212. Wilson, H., De Micco, R., Niccolini, F., Politis, M., Molecular imaging markers to track huntington's disease pathology. Front. Neurol., 8, 2017, 11.
213. Witting, A., Weydt, P., Hong, S., Kliot, M., Moller, T., Stella, N., Endocannabinoids accumulate in spinal cord of SOD1 G93A transgenic mice. J. Neurochem. 89 (2004), 1555–1557.
214. Witting, A., Chen, L., Cudaback, E., Straiker, A., Walter, L., Rickman, B., Möller, T., Brosnan, C., Stella, N., Experimental autoimmune encephalomyelitis disrupts endocannabinoid-mediated neuroprotection. Proc. Natl. Acad. Sci. U.S.A. 103 (2006), 6362–6367.
215. Xia, R., Samad, T.A., Btesh, J., Jiang, L.H., Kays, I., Stjernborg, L., Dekker, N., TRPV1 signaling: mechanistic understanding and therapeutic potential. Curr. Top Med. Chem. 1117 (2011), 2180–2191.
216. Yiangou, Y., Facer, P., Durrenberger, P., Chessell, I.P., Naylor, A., Bountra, C., Banati, R.R., Anand, P., COX-2, CB2 and P2 × 7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC Neurol., 6, 2006, 12.
217. Zajicek, J., Fox, P., Sanders, H., Wright, D., Vickery, J., Nunn, A., Thompson, A., UK MS Research Group, Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis CAMS study: multicentre randomised placebo-controlled trial. Lancet 362 (2003), 1517–1526.
218. Zajicek, J.P., Sanders, H.P., Wright, D.E., Vickery, P.J., Ingram, W.M., Reilly, S.M., Nunn, A.J., Teare, L.J., Fox, P.J., Thompson, A.J., Cannabinoids in multiple sclerosis CAMS study: safety and efficacy data for 12 months follow up. J. Neurol. Neurosurg. Psychiatry 76 (2005), 1664–1669.
219. Zajicek, J., Ball, S., Wright, D., Vickery, J., Nunn, A., Miller, D., Gomez Cano, M., McManus, D., Mallik, S., Hobart, J., CUPID investigator group, Effect of dronabinol on progression in progressive multiple sclerosis CUPID: a randomised, placebo-controlled trial. Lancet Neurol. 12 (2013), 857–865.
220. Zettl, U.K., Rommer, P., Hipp, P., Patejdl, R., Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis. Ther. Adv. Neurol. Disord. 9 (2016), 9–30.
221. Zhang, M., Martin, B.R., Adler, M.W., Razdan, R.J., Kong, W., Ganea, D., Tuma, R.F., Modulation of cannabinoid receptor activation as a neuroprotective strategy for EAE and stroke. J. Neuroimmune Pharmacol. 4 (2009), 249–259.
222. Zhao, P., Ignacio, S., Beattie, E.C., Abood, M.E., Altered presymptomatic AMPA and cannabinoid receptor trafficking in motor neurons of ALS model mice: implications for excitotoxicity. Eur. J. Neurosci. 27 (2008), 572–579.
223. Zuardi, A.W., Crippa, J.A., Hallak, J.E., Pinto, J.P., Chagas, M.H., Rodrigues, G.G., Dursun, S.M., Tumas, V., Cannabidiol for the treatment of psychosis in Parkinson's disease. J. Psychopharmacol. 23 (2009), 979–983.
224. Zuccato, C., Valenza, M., Cattaneo, E., Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol. Rev. 903 (2010), 905–981.
225. de Lago, E., Ligresti, A., Ortar, G., Morera, E., Cabranes, A., Pryce, G., Bifulco, M., Baker, D., Fernandez-Ruiz, J., Di Marzo, V., In vivo pharmacological actions of two novel inhibitors of anandamide cellular uptake. Eur. J. Pharmacol. 484 (2004), 249–257.
226. van Esbroeck, A.C.M., Janssen, A.P.A., Cognetta, A.B., Ogasawara, D., Shpak, G., Van der Kroeg, M., Kantae, V., Baggelaar, M.P., de Vrij, F.M.S., Deng, H., Allarà M., Fezza, F., Lin, Z., Van der Wel, T., Soethoudt, M., Mock, E.D., Den Dulk, H., Baak, I.L., Florea, B.F., Hendriks, G., De Petrocellis, L., Overkleeft, H.S., Hankemeier, T., De Zeeuw, C.I., Di Marzo, V., Maccarrone, M., Cravatt, B.F., Kushner, B.F., Van der Stelt, S.A., Activity-based protein profiling reveals off-target proteins of the Fatty Acid Amide Hydrolase inhibitor BIA 10-2474. Science 356 (2017), 1084–1087.
227. van den Elsen, G.A., Ahmed, A.I., Verkes, R.J., Kramers, C., Feuth, T., Rosenberg, P.B., van der Marck, M.A., Olde Rikkert, M.G., Tetrahydrocannabinol for neuropsychiatric symptoms in dementia: a randomized controlled trial. Neurology 84 (2015), 2338–2346.
228. van der Stelt, M., Veldhuis, W.B., Bär, P.R., Veldink, G.A., Vliegenthart, J.F., Nicolay, K., Neuroprotection by Delta9-tetrahydrocannabinol, the main active compound in marijuana, against ouabain-induced in vivo excitotoxicity. J. Neurosci. 21 (2001), 6475–6479.
229. van der Stelt, M., van Kuik, J.A., Bari, M., van Zadelhoff, G., Leeflang, B.R., Veldink, G.A., Finazzi-Agrò A., Vliegenthart, J.F., Maccarrone, M., Oxygenated metabolites of anandamide and 2-arachidonoylglycerol: conformational analysis and interaction with cannabinoid receptors, membrane transporter, and fatty acid amide hydrolase. J. Med. Chem. 45 (2002), 3709–3720.
230. van der Stelt, M., Mazzola, C., Esposito, G., Matias, I., Petrosino, S., De Filippis, D., Micale, V., Steardo, L., Drago, F., Iuvone, T., Di Marzo, V., Endocannabinoids and β-amyloid-induced neurotoxicity in vivo: effect of pharmacological elevation of endocannabinoid levels. Cell. Mol. Life Sci. 63 (2006), 1410–1424.
231. Zygmunt, P.M., Petersson, J., Andersson, D.A., Chuang, H., Sørgård, M., Di Marzo, V., Julius, D., Högestätt, E.D., Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400 (1999), 452–457.